Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study;Raggiungimento del target terapeutico nei soggetti avviati al trattamento con statine in pratica clinica. Risultati dallo studio STAR (Statins Target Assessment in Real practice)

Monaldi Archives for Chest Disease - Cardiac Series

Volumn 76, Issue 4, 2011, Pages 160-167

  Esposti, Luca Degli ^a   Sangiorgi, Diego ^a   Arca, Marcello ^b   Vigna, Giovanni B ^c   Buda, Stefano ^a   Esposti, Ezio Degli ^a  

^a Economics and Outcomes Research   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Adherence treatment; Clinical practice; Hypercholesterolemia; LDL cholesterol; Therapeutic target

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; AZETIDINE DERIVATIVE; BIOLOGICAL MARKER; EZETIMIBE; FLUOROBENZENE; MEVINOLIN; PRAVASTATIN; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; SULFONAMIDE;

AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; DRUG RESPONSE; DRUG TARGETING; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; ALGORITHM; BLOOD; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; HYPERCHOLESTEROLEMIA; ITALY; MIDDLE AGED; MULTICENTER STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGED; ALGORITHMS; AZETIDINES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ITALY; LOVASTATIN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRAVASTATIN; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84862570544     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423-27. (Pubitemid 36776152)
2. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164:1427-36. (Pubitemid 38937854)
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
4. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy of cholesterol-lowering therapy in 18.686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-25.
5. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; 2:Cd007784.
6. Tonelli M, Lloyd A, Clemen F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011.DOI:10.1503/cmaj.101290.
7. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65.229 participants. Arch Intern Med 2010; 170:1024-31.
8. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170.000 participants in 26 randomised trials. Lancet 2010; 376:1670-81.
9. L'uso dei farmaci in Italia. Rapporto nazionale 2010. Accessibile a: www.agenziadelfarmaco.gov.it/sites/default/files/rapporto-osmed-2010.pdf
10. Penning-van Beest FJA, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007; 28: 154-9.
11. Degli Esposti L, Saragoni S, Battacchi P, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients. Results from an administrative database analysis. Clin Ther 2012; 34:190-9.
12. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and health care cost. Med Care 2005; 43:521-30. (Pubitemid 40847288)
13. Motheral BR, Fairman KA. The use of claims databases for antihypertensive drugs and associated hospitalization. Clin Ther 1997; 19:346-66. (Pubitemid 27239651)
14. Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using health care expenditures for healthcare claims data for outcome research and pharmaco-economic analyses. Pharmacoeconomics 1999; 16:1-8. (Pubitemid 29330467)
15. Degli Esposti L, Valpiani G, Baio GL. Valutare l'efficacia degli interventi in sanità. Guida alla raccolta ed alla gestione dei dati clinici ed amministrativi. Il Pensiero Scientifico. Roma (2002).
16. Degli Esposti L, Saragoni S, Buda S, et al. The awareness of albuminuria in an Italian population-based cohort of subjects treated with hypoglicaemic drugs. Journal of Nephrology. In press.
17. Degli Esposti L, Sangiorgi D, Di Pasquale G, et al. Adherence to treatment and anticoagulation control in vitamin K antagonists-treated patients: an administrative databases analysis in a large Italian population. Farmeconomia e Percorsi Terapeutici 2011; 12:63-9.
18. Nota Ministeriale AIFA 13.
19. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute; 2001.
20. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol rogram Adult Treatment Panel III Guidelines. Circulation 2004; 110:227-39. (Pubitemid 38924592)
21. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3:417-26. (Pubitemid 32066649)
22. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - The PRIMO Study. Cardiovasc Drugs Ther 2005; 19: 403-14. (Pubitemid 43228152)
23. Brown WV. Safety of statins. Curr Opin Lipidol 2008; 19: 558-62.